ArticleDiscover oncology2025
LncRNA MANCR is downregulated in non-small cell lung cancer and predicts poor survival.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Harnessing plasma transcriptomics for non-invasive cancer biomarker identification: a comprehensive review.Discover oncology · 2025Review
- The Regulatory Role of LncRNAs in Modulating Autophagy and Drug Resistance in Non-Small-Cell Lung Cancer: Focus on Targeted Therapeutic Approaches.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundIt is known that genomic instability contributes to cancer development. Mitotically associated long non-coding RNA (MANCR) has been reported to promote genomic stability, suggesting its involvement in cancers. Therefore, this study was conducted to investigate the role of MANCR in non-small cell lung cancer (NSCLC).
methodsAfter NSCLC (n = 60) and control (healthy subjects, n = 60) plasma samples, as well as NSCLC and paired non-tumor tissues from patients were collected, the levels of MANCR expression in plasma and tissues was detected using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). Then the correlations of MANCR expression with clinical stages were confirmed. The diagnostic values of MANCR in both plasma and tissue samples for stage I/II NSCLC were analyzed using Receiver Operating Characteristic (ROC) curves. All NSCLC patients were monitored for 5 years to investigate the role of MANCR in the prediction of patients' survival.
resultsMANCR expression was downregulated in both NSCLC plasma and tissue of NSCLC patients compared to controls (P < 0.05). Decreased MANCR expression levels from stage I to IV were observed. However, MANCR expression in non-tumor tissue was not significantly different between different stages (P > 0.05). Additionally, stage I/II NSCLC patients were separated from controls using MANCR in plasma and tumor tissues as biomarkers. Lower MANCR levels in plasma and tumor were closely correlated with patients' higher mortality rate.
conclusionMANCR is down-expressed in NSCLC patients and may serve as a diagnostic and prognostic biomarker for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.